Acetazolamide for central serous retinopathy

Pikkel, Joseph

doi:10.1016/s0161-6420(02)01157-0

Cited by 121 publications

(67 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Treatment with acetazolamide might shorten the duration of the disease without influencing the final visual acuity or recurrence rate. 35 Other medical treatments such as mifepristone, aspirin, finasteride, and propanolol have been reported with good results but require well-designed randomized controlled study to evaluate their efficacy and safety. [36][37][38][39] One of the traditional treatments is focal laser photocoagulation, although its application is limited because of possible scotoma or secondary CNV when the RPE leak is close to the fovea.…”

Section: Discussionmentioning

confidence: 99%

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Younghae

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To review and evaluate the effects of intravitreal bevacizumab injection (IVB) in centralserous chorioretinopathy (CSC) by meta-analysis. Patients and methods Clinical controlled studies that evaluated the effect of IVB in CSC were identified through systematic searches of Embase, PubMed, and the Cochrane Central Register of Controlled Trials. Data on the bestcorrected visual acuity (BCVA) in logMAR and central macular thickness (CMT) in mm at baseline and 6 months after IVB were extracted and compared with those treated by simple observation.Results Four clinical controlled studies were included in the meta-analysis. The IVB injection group achieved better BCVA at a follow-up of 6 months. However, the analysis showed that there were no significant differences of BCVA at 6 months after injection between IVB group and the observation group ( À 0.02 logMAR, 95% CI À 0.14 to 0.11, P ¼ 0.80). The analysis of the reduction in CMT revealed that the difference between groups was not statistically significant ( À 8.37 lm, 95% CI À 97.26 to 80.52, P ¼ 0.85). No report assessed severe complications or side effects of IVB in patients with CSC. Conclusions Meta-analysis failed to verify the positive effect of IVB in CSC based on the epidemiological literature published to date.

show abstract

Section: Discussionmentioning

confidence: 99%

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Younghae

et al. 2013

Eye

View full text Add to dashboard Cite

show abstract

“…Various treatments, including focal photocoagulation, photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) intravitreal injections, corticosteroid antagonists, and acetazolamide have been used to promote the remission of persistent or recurrent CSC. [9][10][11][12][13][14] Intravitreal bevacizumab (IVB), a recombinant humanized monoclonal anti-VEGF antibody, has been reported to be effective in CSC patients with symptom durations over 3 months. 9,[15][16][17][18][19][20] In acute CSC of o3 months symptom duration, IVB may not result in therapeutic benefits compared with simply waiting for spontaneous resolution.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients

Kim

Rim

Lee

et al. 2015

Eye

View full text Add to dashboard Cite

“…[24][25][26] Other reports investigated anti-mineralocorticoids, such as eplerenone [43][44][45][46] and spironolactone, 47,48 as well as carbonic anhydrase inhibitors (acetazolamide). 49 We note that all these series were small (under 20 patients) with relatively short follow-up, and reported mixed results. A reduction in CMT and SRF was noted with the three anti-glucocorticoids, although no change in VA was achieved with ketoconazole and mifepristone.…”

Section: Discussionmentioning

confidence: 84%

“…[43][44][45][46][47][48] Acetazolamide was shown to reduce CMT but had no effect on VA, and it too can cause low blood pressure and other adverse effects. 49 Finasteride is approved by the FDA for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia, and is known to have an excellent safety profile, [51][52][53] and has also been shown to have fewer side effects and drug interactions than ketoconazole. 54 Its most common adverse effect is decreased libido, and no laboratory workup is required except for monitoring of prostate-specific antigen in men with BPH who are using it long-term.…”

Section: Discussionmentioning

confidence: 99%

Finasteride is effective for the treatment of central serous chorioretinopathy

Moisseiev

Holmes

Moshiri

et al. 2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate the safety and efficacy of finasteride treatment in patients with central serous chorioretinopathy (CSC). Methods Retrospective review of 29 eyes of 23 patients who were treated with finasteride for CSC. Previous medical and ocular history, steroid use, length of finasteride treatment, additional treatments for CSC, visual acuity (VA), central macular thickness (CMT), and presence of subretinal fluid (SRF) throughout the follow-up period, and the occurrence of any complications were recorded. Results Initial VA was 0.29 ± 0.31 logMAR, and a trend towards improved VA was noted after 3 months (0.25 ± 0.36 logMAR; P = 0.07). VA was significantly improved at the final follow-up (0.23 ± 0.27 logMAR; P = 0.024). Initial CMT was 354 ± 160 μm, and was significantly reduced after 1 month of treatment (284 ± 77 μm; P = 0.002) and this was maintained to the end of follow-up (247 ± 85 μm; P = 0.001). A significant reduction in SRF presence was found at all time points, with an overall 75.9% rate of complete resolution. Following discontinuation, SRF recurrence was noted in 37.5% of cases. No adverse events were recorded. Conclusions Finasteride is a safe and effective treatment for CSC. It may be a possible new option for the initial management of patient with CSC, and a suggested treatment approach is presented.

show abstract

Acetazolamide for central serous retinopathy

Cited by 121 publications

References 7 publications

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients

Finasteride is effective for the treatment of central serous chorioretinopathy

Contact Info

Product

Resources

About